Enlightenment

Why are organisational cover-ups so common?

Retrieved on: 
Martedì, Maggio 28, 2024

However, as another example of dysfunctional organisational behaviour, it was expected rather than exceptional.

Key Points: 
  • However, as another example of dysfunctional organisational behaviour, it was expected rather than exceptional.
  • They represent what happens when there is a move within organisations and institutions to cover up the causes of a tragedy.
  • My field (organisational behaviour) has contributed to this problem by being servants to industry.
  • But it can lead to a blind spot around how organisational systems can evolve to damage people.
  • But organisational scandals are a reminder of what happens when efficiency is championed over personal experiences, and dysfunctional systems are defended.

Can organisations change?

2024 Winter Fancy Food Show Showcases Over 1,000 Exhibitors, New Products and Trends to Watch

Retrieved on: 
Martedì, Febbraio 6, 2024

"As expected, the show was well executed and extremely productive for us. We had the opportunity to sit with key partners as well as to meet new players in the specialty world. Plus, we loved the cheese-related presentations--very engaging and fun." – Zoe Brickley, Director of Communications & E-Commerce, Jasper Hill Farm

Key Points: 
  • "As the kick-off event of 2024, this year's Winter Fancy Food Show gave us so much to be excited about.
  • – Zoe Brickley, Director of Communications & E-Commerce, Jasper Hill Farm
    "The Fancy Food Shows are always the most productive shows we attend and the 2024 Winter show was the best one yet.
  • – Dina DiCenso, Co-Founder, RIND LLC
    "This year's Winter Fancy Food Show was an amazing showcase of the diversity and innovation in the specialty food space.
  • The next Fancy Food Shows are the 2024 Summer Fancy Food Show , June 23-25 in New York, and the 2025 Winter Fancy Food Show , January 19-21 in Las Vegas.

Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts

Retrieved on: 
Lunedì, Febbraio 5, 2024

“Candel is focused on delivering key value drivers to maximize the impact of its assets and to create substantial value to patients and other stakeholders.

Key Points: 
  • “Candel is focused on delivering key value drivers to maximize the impact of its assets and to create substantial value to patients and other stakeholders.
  • In 2023, we received Fast Track Designation from the FDA for CAN-2409, our most advanced product candidate, for both NSCLC and pancreatic cancer.
  • This platform is open for collaborations with external partners.”
    The Company's strategic prioritization of programs highlights Candel Therapeutics' commitment to operational excellence and efficiency.
  • This approach positions the Company for sustained success in the current dynamic market for new cancer therapeutics.

NWTN and Partners to Exhibit Technologies for Full Clean Energy Value Chain at COP28 in Dubai, UAE

Retrieved on: 
Lunedì, Novembre 27, 2023

DUBAI, UAE, Nov. 27, 2023 /PRNewswire/ -- NWTN Inc. (Nasdaq: NWTN), an eco-conscious mobility technology company bringing passenger-centric green premium mobility solutions to the world ("NWTN" or the "Company"), today announced plans to exhibit, with its partners, technologies for the entire clean energy value chain during COP28 UAE from November 30, 2023 to December 12, 2023 in Dubai, United Arab Emirates.

Key Points: 
  • NWTN exhibit to feature augmented reality interactive experience that guides visitors through the entire clean energy value chain and highlights how NWTN and its partners aim to develop solutions from energy generation to energy storage, and energy utilization.
  • DUBAI, UAE, Nov. 27, 2023 /PRNewswire/ -- NWTN Inc. (Nasdaq: NWTN), an eco-conscious mobility technology company bringing passenger-centric green premium mobility solutions to the world ("NWTN" or the "Company"), today announced plans to exhibit, with its partners, technologies for the entire clean energy value chain during COP28 UAE from November 30, 2023 to December 12, 2023 in Dubai, United Arab Emirates.
  • The exhibit will feature a unique augmented reality interactive experience that guides visitors through the entire clean energy value chain story, from energy generation to energy storage and energy utilization.
  • NWTN is working with its partners to provide and facilitate the clean energy and technology solutions required for rapidly growing economies like the UAE.

NWTN and Partners to Exhibit Technologies for Full Clean Energy Value Chain at COP28 in Dubai, UAE

Retrieved on: 
Lunedì, Novembre 27, 2023

DUBAI, UAE, Nov. 27, 2023 /PRNewswire/ -- NWTN Inc. (Nasdaq: NWTN), an eco-conscious mobility technology company bringing passenger-centric green premium mobility solutions to the world ("NWTN" or the "Company"), today announced plans to exhibit, with its partners, technologies for the entire clean energy value chain during COP28 UAE from November 30, 2023 to December 12, 2023 in Dubai, United Arab Emirates.

Key Points: 
  • NWTN exhibit to feature augmented reality interactive experience that guides visitors through the entire clean energy value chain and highlights how NWTN and its partners aim to develop solutions from energy generation to energy storage, and energy utilization.
  • DUBAI, UAE, Nov. 27, 2023 /PRNewswire/ -- NWTN Inc. (Nasdaq: NWTN), an eco-conscious mobility technology company bringing passenger-centric green premium mobility solutions to the world ("NWTN" or the "Company"), today announced plans to exhibit, with its partners, technologies for the entire clean energy value chain during COP28 UAE from November 30, 2023 to December 12, 2023 in Dubai, United Arab Emirates.
  • The exhibit will feature a unique augmented reality interactive experience that guides visitors through the entire clean energy value chain story, from energy generation to energy storage and energy utilization.
  • NWTN is working with its partners to provide and facilitate the clean energy and technology solutions required for rapidly growing economies like the UAE.

Ascendis Pharma Reports Third Quarter 2023 Financial Results

Retrieved on: 
Martedì, Novembre 7, 2023

Topline results from Phase 3 foresiGHt Trial in adult growth hormone deficiency expected in the fourth quarter of 2023, potentially opening a new label expansion opportunity.

Key Points: 
  • Topline results from Phase 3 foresiGHt Trial in adult growth hormone deficiency expected in the fourth quarter of 2023, potentially opening a new label expansion opportunity.
  • As of September 30, 2023, Ascendis Pharma had cash, cash equivalents, and marketable securities totaling €455.4 million compared to €742.9 million as of December 31, 2022.
  • Ascendis Pharma will host a conference call and webcast today at 4:30 pm Eastern Time (ET) to discuss its third quarter 2023 financial results.
  • The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com .

Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITC

Retrieved on: 
Sabato, Novembre 4, 2023

“We aim to leverage artificial intelligence and machine learning to expedite various aspects of drug discovery and development,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel.

Key Points: 
  • “We aim to leverage artificial intelligence and machine learning to expedite various aspects of drug discovery and development,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer of Candel.
  • “Tumor resistance to immunotherapy is driven by multiple mechanisms, which are heterogeneous in nature,” said Francesca Barone, MD, PhD, Chief Scientific Officer at Candel.
  • “The Alpha-201-macro1 preclinical data presented today support the utility of local delivery of an immunologically active, multimodal agent as a potential alternative to systemic therapy.
  • We are excited to leverage the enLIGHTEN™ Discovery Platform to optimize the immunostimulatory payload of this agent for activation of innate immune surveillance with the goal of maximizing its therapeutic potential.”
    Further details from the posters are available on the Candel website at: www.candeltx.com/media

SoftIron Recognized as a Sample Vendor in Gartner® Hype Cycle™ for Edge Computing

Retrieved on: 
Lunedì, Ottobre 23, 2023

The five phases of a Hype cycle are innovation trigger, Peak of Inflated Expectations, Trough of Disillusionment, Slope of Enlightenment and the Plateau of Productivity.

Key Points: 
  • The five phases of a Hype cycle are innovation trigger, Peak of Inflated Expectations, Trough of Disillusionment, Slope of Enlightenment and the Plateau of Productivity.
  • Gartner predicts that infrastructure and operations (I&O) leaders are beginning the process of laying out a strategy for how they intend to manage data at the edge.
  • “We are excited to be recognized in the 2023 Garter Hype Cycle for Edge Computing,” said Jason Van der Schyff, COO at SoftIron.
  • “We believe at SoftIron to be well positioned to help our customers address and take advantage of the latest trends and developments in Edge Computing as reported in Gartner’s Hype Cycle.”
    For complimentary access to the 2023 Gartner Hype Cycle for Edge Computing and to read in-depth insights from Gartner, visit the SoftIron website: https://softiron.com/gartner-hype-cycle-for-edge-computing-2023/.

Explainer: the philosophy of Jean-Jacques Rousseau is profoundly contemporary

Retrieved on: 
Lunedì, Settembre 25, 2023

No account of the modern era – not just modern thought – could ignore him.

Key Points: 
  • No account of the modern era – not just modern thought – could ignore him.
  • But like any major thinker, there are risks in summaries – some of which give us clues about Rousseau himself.
  • Although he is known as a social and political philosopher, Rousseau’s creative output does not resemble that of a contemporary “theorist”.
  • These are now conventional tropes, but they were only emerging at the time Rousseau was writing.

Natural or artificial

    • Rousseau had shot to fame a decade earlier, after winning an essay competition advertised in the literary magazine Mercure de France.
    • Where much philosophical discussion had been centred around the distinction between the “natural” and the “supernatural”, Rousseau opposed the natural to the artificial.
    • He argued that what we ordinarily think of as civilisational progress creates – and then aims to satisfy – new and artificial vices, serving our vanity and not our natural needs.
    • In fact, he proposed there were many good reasons to think they were greater in both.
    • Read more:
      Guide to the Classics: Voltaire’s Candide — a darkly satirical tale of human folly in times of crisis

Society and inequality

    • Developing these ideas, in 1754, Rousseau wrote his Discourse on the Origin and Basis of Inequality Among Men.
    • In it, he attempted a thought experiment which imagined what humans may have been like in a “pre-civilisational” state.
    • Rousseau was aware that this act of imagination was speculative and he could not be sure of its results.
    • He held that inequality was artificial.

Education and politics

    • The first was the institution of a new kind of education; the second was reorienting politics towards a new moral foundation.
    • In Émile, or On Education (1862), Rousseau wrote a treatise on education in the form of a bildungsroman – the first and likely the last of its kind.
    • He sought to outline the conditions of a good education, which he thought should be based on lived experience and the development of individual character, not rote learning, mechanical memorisation, or even the reading of books.
    • As for moral education, young people should learn about the consequences of their actions.
    • Rousseau’s terminology has oriented discussions of morality, self-development and politics from the 18th century to the counterculture of the 1960s, the New Age movement of the 1980s, and beyond.

Deism and human nature

    • According to Rousseau, we know what we know of God from Nature and Reason alone.
    • In Rousseau, Judge of Jean-Jacques (1776), Rousseau addresses this question directly, and in typically Rousseauian fashion:
      whence could the painter and apologist of human nature have taken his model, if not from his own heart?
    • He has described this nature just as he felt it within himself.
    • whence could the painter and apologist of human nature have taken his model, if not from his own heart?
    • He has described this nature just as he felt it within himself.

Ascendis Pharma Presents Results from Long-Term enliGHten Trial of TransCon™ hGH in Pediatric Growth Hormone Deficiency

Retrieved on: 
Sabato, Settembre 23, 2023

COPENHAGEN, Denmark, Sept. 23, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced results from enliGHten, the Company’s open-label extension trial evaluating the long-term safety and efficacy of TransCon hGH as a once-weekly treatment for children and adolescents with growth hormone deficiency (GHD). Results were shared today in Poster LB-17 at ESPE 2023, the annual meeting of the European Society for Paediatric Endocrinology being held in The Hague, September 21-23.

Key Points: 
  • COPENHAGEN, Denmark, Sept. 23, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced results from enliGHten, the Company’s open-label extension trial evaluating the long-term safety and efficacy of TransCon hGH as a once-weekly treatment for children and adolescents with growth hormone deficiency (GHD).
  • The enliGHten trial enrolled 298 participants (mean age 10.3 years) from the Phase 3 heiGHt Trial of treatment-naïve pediatric GHD patients and the Phase 3 fliGHt Trial of pediatric GHD patients switching from daily somatropin treatment.
  • Of these treatment completers, 59% met or exceeded their average parental height SDS, with mean TransCon hGH treatment duration of 3.2 years.
  • “Additionally, these results demonstrate that long-term treatment goals can be safely reached with TransCon hGH administered once weekly.”
    TransCon hGH was generally safe and well-tolerated.